18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent

European Urology

Volumn 63, Issue 5, 2013, Pages 792-796

  Tilki, Derya ^a   Reich, Oliver ^a,b   Graser, Anno ^a   Hacker, Marcus ^a   Silchinger, Jürgen ^a   Becker, Armin J ^a   Khoder, Wael ^a   Bartenstein, Peter ^a   Stief, Christian G ^a   Loidl, Wolfgang ^a,c   Seitz, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Klinikum Harlaching   (Germany)

^c Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

Author keywords

Choline PET CT; Positron emission tomography; Prostate cancer; Radical prostatectomy

Indexed keywords

FLUOROETHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; WHOLE BODY PET;

AGED; CHOLINE; DISEASE PROGRESSION; HUMANS; KALLIKREINS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REOPERATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; WHOLE BODY IMAGING;

EID: 84876065990     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.003     Document Type: Article

References (21)

1. B.D. Guillonneau, and K. Fizazi Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news? Eur Urol 59 2011 900 901
2. M.N. Simmons, A.J. Stephenson, and E.A. Klein Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy Eur Urol 51 2007 1175 1184
3. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
4. S. Sivalingam, J. Oxley, J.L. Probert, J.U. Stolzenburg, and H. Schwaibold Role of pelvic lymphadenectomy in prostate cancer management Urology 69 2007 203 209
5. A.M. Hovels, R.A. Heesakkers, and E.M. Adang The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis Clin Radiol 63 2008 387 395
6. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80
7. M. Picchio, C. Messa, and C. Landoni Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography J Urol 169 2003 1337 1340
8. D. Schilling, H.P. Schlemmer, and P.H. Wagner Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer BJU Int 102 2008 446 451
9. V. Scattoni, M. Picchio, and N. Suardi Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy Eur Urol 52 2007 423 429
10. H. Jadvar Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease Clin Nucl Med 36 2011 754 756
11. M.H. Poulsen, K. Bouchelouche, and O. Gerke [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study BJU Int 106 2010 639 643 discussion 644
12. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
13. G. Giannarini, G. Petralia, and H.C. Thoeny Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature Eur Urol 61 2012 326 340
14. T. Budiharto, S. Joniau, and E. Lerut Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases Eur Urol 60 2011 125 130
15. G. Giovacchini, M. Picchio, and E. Coradeschi Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 2010 301 309
16. C. Fuccio, R. Schiavina, and P. Castellucci Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study Eur J Nucl Med Mol Imaging 38 2011 1985 1989
17. M. Beheshti, R. Vali, and P. Waldenberger The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT Mol Imaging Biol 11 2009 446 454
18. M. Beheshti, L. Imamovic, and G. Broinger 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients Radiology 254 2010 925 933
19. B. Scher, M. Seitz, and W. Albinger Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer Eur J Nucl Med Mol Imaging 34 2007 45 53
20. R. Schiavina, V. Scattoni, and P. Castellucci 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms Eur Urol 54 2008 392 401
21. D.B. Husarik, R. Miralbell, and M. Dubs Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 253 263